Mylan and Teva Pharmaceuticals have been at the center of probes into allegations that generic-drug companies coordinated with one another on setting prices.

Deeply indebted companies or those with medicines that are heavily used by Medicare recipients or subject to rebating may be most exposed.

Both Amazon and UnitedHealth have recently announced new tools to improve medical record access. Who has the advantage?